Oral MS drug Cladribine rejected by European drug agency

Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
Post Reply
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm

Oral MS drug Cladribine rejected by European drug agency

Post by MSUK » Fri Sep 24, 2010 1:32 am


European regulators rejected Merck KGaA’s multiple sclerosis pill cladribine, the second setback this week for the German drugmaker seeking to compete with Novartis AG for a share of a new market.

The European Medicines Agency found the medicine’s benefits don’t outweigh the risks, Darmstadt, Germany-based Merck said in a statement today. Merck is weighing an appeal and still believes cladribine has the potential to generate $1 billion in revenue a year, said Elmar Schnee, head of the company’s drug unit, in a telephone interview. The stock dropped the most in seven months.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/

Family Elder
Posts: 1517
Joined: Wed Feb 11, 2009 3:00 pm
Location: California

Post by LR1234 » Fri Sep 24, 2010 2:27 am

Isn't mad that some countries say ok to what could be very dangerous drugs whilst others feel the risk is too high??

Well lets see what happens with the Russian MS patients and the Australian MS patients who take it. I hope it works well and that the cancer risk is minimal. ( I have a feeling though that the cancer risk is probably very high)

Post Reply
  • Similar Topics
    Last post

Return to “Mavenclad (Cladribine)”